Edition:
United States

Proteome Sciences PLC (PRM.L)

PRM.L on London Stock Exchange

18.75GBp
25 Jul 2016
Change (% chg)

-1.25p (-6.25%)
Prev Close
20.00p
Open
19.25p
Day's High
19.25p
Day's Low
18.75p
Volume
365,733
Avg. Vol
225,008
52-wk High
23.94p
52-wk Low
13.00p

Latest Key Developments (Source: Significant Developments)

Proteome Sciences plc announces placing to raise GBP2.5 million
Tuesday, 23 Jun 2015 02:01am EDT 

Proteome Sciences plc:Says that it has conditionally raised about GBP2.5 million, before expenses, through the placing of 13,861,112 new ordinary shares of 1 penny each in the capital of the company at a price of 18 pence per ordinary share.  Full Article

Proteome Sciences announces directorate change
Tuesday, 30 Sep 2014 02:03am EDT 

Proteome Sciences plc:Announces the appointment of Geoffrey Ellis as finance director with effect from Oct. 1.Says James Malthouse will remain as a director of the company until his retirement on Nov. 30.  Full Article

Proteome Sciences PLC gives FY 2015 revenue outlook
Tuesday, 30 Sep 2014 02:01am EDT 

Proteome Sciences PLC:Says strong growth in revenues is expected in FY 2015.FY 2015 revenue of 6.86 mln Pounds - Thomson Reuters I/B/E/S.  Full Article

Proteome Sciences plc signs $2 million contract with Genting TauRx Diagnostic Centre
Thursday, 25 Sep 2014 05:10am EDT 

Proteome Sciences plc:Signs $2 mln contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy London, Sept. 25, 2014.The project will involve PS analysing blood samples from patients enrolled in a phase 3 trial of the experimental Alzheimer's drug LMTX, targeting the tau pathway, and from age-matched controls.LMTX is being developed by TauRx Therapeutics for the treatment for Alzheimer's disease of mild to moderate severity.  Full Article

BRIEF-Proteome Sciences says current year started well

* current year has started well with a strong order book and a growing pipeline in biomarker services Source text for Eikon: Further company coverage: